HOME
LOGIN
THE MEDICAL LETTER
Subscribe
Current Issue
Previous Issues
Reference Tables
Sample Articles
ABOUT US
The Medical Letter, Inc.
CONTINUING EDUCATION
Exams
DRUG INTERACTIONS
PRODUCTS
CONTACT US
The Medical Letter Mobile Home Page
CURRENT
ISSUE
1629
The interleukin-6 (IL-6) receptor antagonist tocilizumab (Actemra – Genentech) has received an Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2 years old who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab has been approved by the FDA for various indications, including rheumatoid arthritis and juvenile idiopathic...  read more...
More from issue 1629
Advance Release
Coming Soon
Myfembree for Fibroid-Associated Heavy Menstrual Bleeding
Ponesimod (Ponvory) for Multiple Sclerosis
Fenfluramine (Fintepla) for Dravet Syndrome
Recommend to Your Library  
Previous Issues
© 2021 The Medical Letter, Inc.